tiprankstipranks
SynAct Pharma AB’s Q1 2025 Interim Report Highlights
PremiumCompany AnnouncementsSynAct Pharma AB’s Q1 2025 Interim Report Highlights
27d ago
SynAct Pharma Secures Extended US Patent for Resomelagon Combination Therapy
Premium
Company Announcements
SynAct Pharma Secures Extended US Patent for Resomelagon Combination Therapy
1M ago
SynAct Pharma to Host Capital Markets Day Amidst Strategic Advancements
Premium
Company Announcements
SynAct Pharma to Host Capital Markets Day Amidst Strategic Advancements
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100